0001209191-18-058222.txt : 20181113 0001209191-18-058222.hdr.sgml : 20181113 20181113161540 ACCESSION NUMBER: 0001209191-18-058222 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181108 FILED AS OF DATE: 20181113 DATE AS OF CHANGE: 20181113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bozigian Haig P. CENTRAL INDEX KEY: 0001423837 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 181178137 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-08 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001423837 Bozigian Haig P. 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Development Officer Common Stock 2018-11-08 4 M 0 19501 8.66 A 155498 D Common Stock 2018-11-08 4 S 0 19501 110.00 D 135997 D Common Stock 2018-11-08 4 M 0 16794 8.65 A 152791 D Common Stock 2018-11-08 4 S 0 16794 110.00 D 135997 D Non-Qualified Stock Option 8.66 2018-11-08 4 M 0 19501 8.66 A 2022-01-12 Common Stock 19501 34547 D Non-Qualified Stock Option 8.65 2018-11-08 4 M 0 16794 8.65 A 2023-01-10 Common Stock 16794 34376 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Option granted January 12, 2012 and vested monthly over four years. Option granted January 10, 2013 and vested monthly over four years. /s/ Darin Lippoldt, Attorney-in-Fact 2018-11-13